Journal of the American Society of Hypertension
Volume 1, Issue 1 , Pages 5-16 , January 2007

Is it the blood pressure or the blood vessel?

  • Jay N. Cohn, MD

      Affiliations

    • Corresponding Author InformationCorresponding author: Jay N. Cohn, MD, Cardiovascular Division, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware Street Southeast, Minneapolis, Minnesota 55455. Tel: 612-625-5646; fax: 612-624-2174.

Received 9 November 2006 ,Accepted 10 November 2006.

References 

  1. Cohn JN. Arteries, myocardium, blood pressure, and cardiovascular risk: towards a revised definition of hypertension. J Hypertens. 1998;16:2117–2124
  2. Giles TD, Berk BC, Black HR, et al. Hypertension Writing Group Expanding the definition and classification of hypertension. J Clin Hypertens. 2005;7:505–512
  3. Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet. 2003;362:1527–1535
  4. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386–392
  5. Sever PS, Poulter NR. Blood pressure reduction is not the only determinant of outcome. Circulation. 2006;113:2754–2763
  6. Elliott WJ, Jonsson C, Black HR. It is not beyond the blood pressure; it is the blood pressure. Circulation. 2006;113:2763–2772
  7. Mulvaney MJ. Remodeling of resistance vessel structure in essential hypertension. Curr Opin Nephrol Hypertens. 1993;2:77–81
  8. Franklin SS, Gustin WIV, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure: the Framingham Heart Study. Circulation. 1997;96:308–315
  9. Cohn JN. Haemodynamic effects of beta blockers. Drugs. 1983;25(suppl 2):100–102
  10. Neaton JD, Wentworth D Multiple Risk Factor Intervention Trial Research Group. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease (Overall findings and differences by age for 316,099 white men). Arch Intern Med. 1992;152:56–64
  11. Kannel WB. Blood pressure as a cardiovascular risk factor. JAMA. 1996;275:1571–1576
  12. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation (Impact of risk factors for coronary atherosclerosis). J Clin Invest. 1995;95:I1747–I1755
  13. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–1052
  14. Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol. 2002;89(suppl 2A):3A–10
  15. Morishita R, Higaki J, Miyazaki M, Ogihara T. Possible role of the vascular renin-angiotensin system in hypertension and vascular hypertrophy. Hypertension. 1992;19(suppl 2):S62–S67
  16. Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for the release of endothelium-derived relaxing factor in the human forearm circulation in vivo: blunted response in essential hypertension. Circulation. 1990;81:1762–1767
  17. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation. 1993;87:1468–1474
  18. Devereux RB, Savage DD, Sachs I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol. 1983;51:171–176
  19. Schelling P, Fisher H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy?. J Hypertens. 1991;9:3–5
  20. Dahlöf B. Left ventricular hypertrophy and angiotensin II antagonists. Am J Hypertens. 2001;14:174–182
  21. Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension. 2002;39:969–975
  22. Everett AD, Tufro-McReddie A, Fisher A, Gomez RA. Angiotensin inhibitors regressed cardiac hypertrophy and transforming growth factor-β 1 expression. Hypertension. 1994;23:587–592
  23. Prabhu SD. Nitric oxide protects against pathological ventricular remodeling: reconsideration of the role of NO in the failing heart. Circ Res. 2004;94:1155–1157
  24. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14–22
  25. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular enterprises (Part II: the aging heart in health: links to heart disease). Circulation. 2003;107:346–354
  26. Neaton J, Wentworth D, Sherwin R, Kittner S, Kuller L, Stamler J The MRFIT Research Group. Comparison of 10 year coronary and cerebrovascular disease mortality rates by hypertensive status for Black and non-Black men screened in the Multiple Risk Factor Intervention Trial (MRFIT) [abstract]. Circulation. 1989;80:II–300
  27. Dahlöf B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003
  28. Dahlöf B, Sever PS, Poulter N, et al. ASCOT Investigators Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906
  29. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit. 2001;6:63–72
  30. Merz CNB, Shaw LJ, Reis SE, et al. WISE Investigators Insights from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006;47:21–30
  31. Yancy CW, Sica DA. Cardiovascular disease in African-Americans. J Clin Hypertens. 2004;6(4 suppl 1):S54–S56
  32. Kikkawa R, Araki S, Haneda M, Kajiwara N, Hidaki H, Shigeta Y. Hypertension and the development of complications in noninsulin dependent diabetes mellitus in Japan. J Am Soc Nephrol. 1992;3:5120–5125
  33. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913
  34. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–2572erratum JAMA 2003;290:197
  35. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effect of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA. 1967;202:1028–1034
  36. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA. 1970;213:1143–1152
  37. Management Committee. The Australian Therapeutic Trial in Mild Hypertension. Lancet. 1980;1:1261–1267
  38. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J. 1985;291:97–104
  39. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension III. Influence of age, diastolic pressure, and prior cardiovascular disease; further analysis of side effects. Circulation. 1972;45:991–1004
  40. Berglund G. The meaning of clinical trials (Controversies in the treatment of hypertension). In:  Laragh JN,  Brenner BM editor. Hypertension: pathophysiology, diagnosis, and management. New York, New York: Raven Press Ltd; 1990;p. 1955–1965
  41. Hansson L, Zanchetti A, Carruthers SG, et al. HOT Study Group Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755–1762
  42. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–153
  43. The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–788
  44. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure (Results of a Veterans Administration Cooperative Study (V-HeFT)). N Engl J Med. 1986;314:1547–1552
  45. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  46. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS-II): a randomized trial. Lancet. 1999;353:9–13
  47. Merit-HF Study Group. Effect of metroprolol CR/XL in chronic heart failure: Metroprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  48. Packer M, Coats AJ, Fowler MB, et al. Carvedilol Prospective Randomized Cumulative Survival Study Group Effect on carvedilol on survival in severe chronic heart failure (COPERNICUS). N Engl J Med. 2001;344:1651–1658
  49. Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49(1:32–39
  50. Sever PS, Dahlöf B, Poulter NR, et al. ASCOT Investigators The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels (The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA)). Lancet. 2003;361:1149–1158
  51. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  52. Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7–22
  53. Svensson P, de Faire U, Sleight P, Yusuf S, Östergren J. Comparative effects of ramipril on ambulatory and office blood pressure: A HOPE substudy. Hypertension. 2001;38:e28–e32
  54. Lewis EJ, Hunsicker LG, Clarke WR, et al. Collaborative Study Group Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860
  55. Lee VC, Rhew DC, Dylan M, Badamgarav E, Braunstein GD, Weingarten SR. Meta-analysis: angiotensin-receptor blockers in chronic heart failure and high-risk acute myocardial infarction. Ann Intern Med. 2004;141:693–704
  56. Lonn E, Yusuf S, Dzavik V, et al. SECURE Investigators Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation. 2001;103:919–925
  57. Lonn E, Shaikholeslami R, Yi Q, et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol. 2004;43:2200–2206
  58. Wong M, Staszewsky L, Latini R, et al. Val-HeFT Heart Failure Trial Investigators Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002;40:970–975
  59. Leibovitz E, Beniashvili M, Zimlichman R, Freiman A, Shargorodsky M, Gavish D. Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients. Am J Hypertens. 2003;16:715–718
  60. Mason RP, Kalinowski L, Madajka M. Combined effects of amlodipine and atorvastatin on endothelial dysfunction in vitro [abstract]. Circulation. 2005;112:II–203
  61. Metra M, Nodari S, Parrinello G, Giubbini R, Manca C, Dei Cas L. Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance. Am Heart J. 2003;145:292–299
  62. Schiffrin EL, Deng LY, Larochelle P. Effects of a β−blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. Hypertension. 1994;23:83–91
  63. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:1967–1975
  64. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN V-HeFT VA Cooperative Studies Group. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure [abstract]. Circulation. 1993;87:VI-1723
  65. Devereux RB, Dahlöf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) trial. Circulation. 2004;110:1456–1462
  66. Dahlöf B, Sever PS, Poulter N, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895–906
  67. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981–2997
  68. Julius S, Kjeldsen SE, Weber M, et al. for the VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363:2022–2031
  69. Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685–1697
  70. Cohn JN, Hoke L, Whitwam W. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J. 2003;146:679–685
  71. Cohn JN, Duprez DA, Grandits GA. Arterial elasticity as part of a comprehensive assessment of cardiovascular risk and drug treatment. Hypertension. 2005;46:217–220
  72. Adams KF, Boehmer JP, Deedwania P, et al. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10–38

 Conflict of interest: none.

PII: S1933-1711(06)00006-4

doi: 10.1016/j.jash.2006.11.001

Journal of the American Society of Hypertension
Volume 1, Issue 1 , Pages 5-16 , January 2007

Article Tools

* Image Usage & Resolution